News

GeneVentiv Therapeutics is developing the first universal gene therapy for all types of hemophilia, including the most difficult cases. By working to bring breakthrough therapies to market, this UNC-affiliated startup is also instilling expanded hope in hemophilia patients who wrestle with the daily realities of their life threatening, inherited disorder.

Durham-based Altis Biosystems is offering a research award of up to $10,000 for a scientific team to use its proprietary drug-development technology in a research project.

For the second year in a row, awards for research conducted at the University of North Carolina at Chapel Hill exceeded $1 billion.

After 11 years of dedicated service and commitment to the University and the state, Judith Cone, vice chancellor for innovation, entrepreneurship and economic development, will retire from Carolina in April.

Frost & Sullivan, a California company specializing in business growth and development, has named Durham’s 410 Medical, Inc. as the 2021 Entrepreneurial Company of the Year in the global fluid resuscitation devices industry.